In 2020, adjuvant platinum-based chemotherapy became the standard of care for patients with muscle-invasive or locally advanced upper tract urothelial carcinoma of the ureter or renal pelvis (UTUC) based on disease-free survival (DFS) data from the POUT trial. Now, an update from POUT confirms that adjuvant treatment improves overall survival (OS) in this rare disease.

In this phase III trial, 261 patients with resected muscle-invasive or node-positive UTUC were randomly assigned 1:1 to receive four cycles of adjuvant gemcitabine plus either cisplatin or carboplatin, or surveillance alone. The primary end point of DFS was met after a median follow-up duration of 30 months (3-year DFS 71% versus 46%; HR 0.45, 95% CI 0.30–0.68; P = 0.0001) and enrolment was stopped, further reducing the statistical power of the OS analysis.

根据 POUT 试验的无病生存 (DFS) 数据，2020 年，辅助铂类化疗成为肌层浸润性或局部晚期输尿管或肾盂上尿路上皮癌 (UTUC) 患者的标准治疗方法。现在，POUT 的最新消息证实辅助治疗可以改善这种罕见疾病的总生存期 (OS)。

在这项 III 期试验中，261 名切除肌肉浸润性或淋巴结阳性 UTUC 的患者按 1:1 随机分配，接受四个周期的辅助吉西他滨加顺铂或卡铂，或单独监测。中位随访时间 30 个月后，达到了 DFS 的主要终点（3 年 DFS 分别为 71% 与 46%；HR 0.45，95% CI 0.30-0.68；P  = 0.0001），并停止入组，进一步减少OS 分析的统计功效。